Table 3.

Summary of publications that have employed the adenovirus-vectorized expression of the hACE2 mouse model of SARS-CoV-2 infection.

AdV Serotype	Promoter	Dose (vg), Route of Administration, and Time Between AAV-hACE2 Transduction and SARS-CoV-2 Challenge	Strain of Mice	Interventions Tested	Reference
Ad5	CMV	2.5 × 108 PFU IN and challenged 5 days later	BALB/c, C57BL/6, IFNAR−/−, STAT1−/−	Venezuelan equine encephalitis replicon particles (VRPs) expressing the SARS-CoV-2 spike (VRP-S), transmembrane (VRP-M), nucleocapsid (VRP-N), and envelope (VRP-E) proteins, human convalescent plasma, two antiviral therapies (poly I:C and remdesivir)	Sun et al., 2020 [55]
Ad5	CMV	2.5 × 108 PFU IN and challenged 5 days later	BALB/c	Anti-SARS-CoV-2 mAb 1B07	Hassan et al., 2020 [56]
Ad5	CMV	2.5 × 108 PFU IN and challenged 5 days later	BALB/c	VSV-eGFP-SARS-CoV-2 vaccine	Case et al., 2020 [57]
Ad5	CMV	7.5 × 107, 1 × 108, or 2.5 × 108 PFU IN and challenged 5 days later	BALB/c C57BL/6	N/A	Wong et al., 2020 [58]
Ad5	CMV/K18	2.5 × 108 PFU IN and challenged 5 days later	BALB/c C57BL/6	N/A	Rathnasinghe et al., 2020 [59]
Ad5	Not provided	1.5 × 109 PFU oropharyngeal and challenged 5 days later	C57BL/6	N/A	Han et al., 2021 [60]
Ad5	Not provided	2.5 × 108 PFU IN; interval between transduction and challenge not specified	BALB/c	SARS-CoV-2 neutralizing antibody P2C-1F11	Ge et al., 2021 [61]
Ad5	Not provided	2.5 × 108 PFU IN and challenged 5 days later	BALB/c C57BL/6	N/A	Zhuang et al., 2021 [62]
Ad5	Not provided	4 × 108 TCID50 IN and challenged 5 days later	IFNAR−/−	SARS-CoV-2 neutralizing antibody PR1077	Fu et al., 2021 [63]
Ad5	Not provided	1.5 × 109 PFU oropharyngeal and challenged 5 days later	C57BL/6	N/A	Liu et al., 2021 [64]
Ad5	Not provided	2.5 × 108 PFU IN and challenged 5 days later	BALB/c	Serine protease inhibitors (camostat mesylate and nafamostat mesylate)	Li et al., 2021 [65]
Ad5	CMV	2.5 × 108 PFU IN and challenged 5 days later	BALB/c	Anti-SARS-CoV-2 mAb NC0321 expressed from IN administered rSIV.F/HN lentiviral vector	Du et al., 2022 [66]
Ad5	CMV	2.5 × 108 PFU IN and challenged 5 days later	C57BL/6	N/A	Yang et al., 2022 [67]
Ad5	CMV	2.5 × 108 PFU IN and challenged 5 days later	C57BL/6	IgY-RBD antibody	El-Kafrawy et al., 2022 [68]
Ad5	CMV	2.5 × 108 PFU IN and challenged 5 days later	IFNAR−/−, STAT1−/−	Investigated whether pre-existing immunity to seasonal CoV spikes could have a protective effect against SARS-CoV-2	Liu et al., 2023 [69]

vg = vector genome, IN = intranasal, IT = intratracheal, IP = intraperitoneal, N/A = not applicable.